Voltage-Gated Sodium Channels as Potential Biomarkers and Therapeutic Targets for Epithelial Ovarian Cancer

Iris S. Brummelhuis, Stephen J. Fiascone, Kathleen T. Hasselblatt, Gyorgy Frendl, and Kevin M. Elias

1 Faculty of Health, Medicine, and Life Sciences, Maastricht University, 6200 MD Maastricht, The Netherlands; iris.brummelhuis@radboudumc.nl
2 Surgical ICU Translational Research Center, Brigham and Women’s Hospital, Boston, MA 02115, USA; gfrendl@bwh.harvard.edu
3 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA; Stephen.Fiascone@bmc.org (S.J.F); k hasselblatt@bwh.harvard.edu (K.T.H.)
4 Dana-Farber Cancer Institute, Boston, MA 02115, USA
5 Harvard Medical School, Boston, MA 02115, USA
6 Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA

Correspondence: kelias@bwh.harvard.edu; Tel.: +617-732-8840; Fax: +617-738-5124

Abstract: Abnormal ion channel expression distinguishes several types of carcinoma. Here, we explore the relationship between voltage-gated sodium channels (VGSC) and epithelial ovarian cancer (EOC). We find that EOC cell lines express most VGSC, but at lower levels than fallopian tube secretory epithelial cells (the cells of origin for most EOC) or control fibroblasts. Among patient tumor samples, lower SCN8A expression was associated with improved overall survival (OS) (median 111 ± 52 months; HR 2.04 95% CI: 1.21–3.44; p = 0.007), while lower SCN1B expression was associated with poorer OS (median 45 vs. 56 months; HR 0.69 95% CI: 0.54–0.87; p = 0.002). VGSC blockade using either anti-epileptic drugs or local anesthetics (LA) decreased the proliferation of cancer cells. LA increased cell line sensitivity to platinum and taxane chemotherapies. While lidocaine had similar additive effects with chemotheraphy among EOC cells and fibroblasts, bupivacaine showed a more pronounced impact on EOC than fibroblasts when combined with either carboplatin (ΔAUC ~ 37% vs. ~ 16%, p = 0.003) or paclitaxel (ΔAUC ~ 37% vs. ~ 22%, p = 0.02). Together, these data suggest VGSC are prognostic biomarkers in EOC and may inform new targets for therapy.

Keywords: high-grade serous ovarian cancer; sodium channels; local anesthetics

1. Introduction

Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death among women in developed countries [1]. EOC is treated with a combination of surgical
cytoreduction and platinum-based chemotherapy. Primary remission rates are high, but most patients develop recurrence within three years, with an extremely low rate of salvage [2]. Despite this adverse prognosis, there remains a sizable minority of patients with EOC, even with advanced-stage disease on presentation, who achieve long-term survival rates exceeding ten years [3]. Understanding the factors that contribute to the more favorable prognoses in these cases has the potential to inform novel treatment strategies for the larger share of women with EOC.

Abnormal ion channel expression distinguishes several types of carcinoma, including breast, colon, pancreatic, prostate, lung, esophageal, and gastric cancers [4,5]. Ion channels not only have a role as prognostic biomarkers, but also as potential therapeutic targets using several classes of existing pharmacologic compounds [6]. Among the various channel types, voltage-gated sodium channels (VGSC) have received particular interest because VGSC activity appears to potentiate the invasiveness and metastatic potential of carcinoma cells [7–10]. Indeed, preclinical data suggest that VGSC blockade using either anti-epileptic drugs (AEDs) or local anesthetics (such as lidocaine or bupivacaine) may inhibit tumor growth and metastasis [11–19].

While few patients with EOC will be exposed to AEDs, many will receive local anesthetic agents. As with AEDs, local anesthetics appear to encourage tumor cell apoptosis and inhibit tumor migration. In the past, the translational relevance of this finding was limited because patients were primarily exposed only to small doses of local anesthetics via local wound infiltration. However, modern enhanced recovery after surgery (ERAS®) protocols have dramatically increased utilization of local anesthetics due to an emphasis on opioid-sparing perioperative management [20,21]. These techniques produce greater systemic exposure to local anesthetics, either from continuous bupivacaine or lidocaine neuraxial analgesia catheters (which can produce notable serum levels of drug) or continuous intravenous lidocaine infusions [22–25]. Whether these changes in analgesic management may affect cancer outcomes has been a topic of considerable debate, both for ovarian cancer as well as other malignancies [26–35]. As the role of VGSC channel expression in EOC has not been extensively studied, we sought to understand the prognostic value of VGSC expression in EOC tumors and to explore the effects of VGSC inhibition on EOC cells.

2. Materials and Methods

2.1. IRB Approval

This study was approved by Mass General Brigham Institutional Review Board under protocol #2016P002742.

2.2. RNAseq Data

RNAseq data regarding VGSC expression for 48 different ovarian cancer cell lines were downloaded from the Cancer Cell Line Encyclopedia (CCLE), a publicly available dataset from the Broad Institute (Cambridge, MA USA) [36,37]. RNAseq expression sets measured in log_2 Robust Multiarray Average (RMA) units were downloaded from the CCLE webserver [https://portals.broadinstitute.org/ccle/] (accessed on 7 January 2018). RNAseq data comparing VGSC expression between three EOC cell lines (KURAMOCHI, OVSAHO, and JHOS4) and three immortalized benign fallopian tube cell lines (FT33, FT194, and FT246) were downloaded in fragments per kilobase per million mapped reads (FPKM) from the Gene Expression Omnibus, accession number GSE83101 [38]. Sequence tags were mapped to the reference genome Hg19 using TopHat v2.0.6 (Johns Hopkins University, Baltimore, MD USA), and transcript levels were calculated in FPKM using Cufflinks v2.0.2 (Johns Hopkins University, Baltimore, MD USA). Differential expression was determined with CuffDiff, using Chi-square tests with 1 degree of freedom and two-tailed p-values to assess statistical significance [39]. Adjusted p-values were calculated using a Bonferroni correction for multiple testing. RNA-seq data appear in Supplemental Datasets S1 and S2.
2.3. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

RNA was extracted from the EOC lines KURAMOCHI and OVCAR5 and the fibroblast cell lines BJ and WI-38 using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) and chloroform (Fisher Scientific, Fair Lawn, NJ, USA) then quantified using a NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). RNA quality was assessed by UV spectroscopy. RNA was then diluted to 40 ng/ul, and reverse transcription was performed using the TaqMan Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) to generate cDNA. Quantitative PCR was performed using TaqMan Array Human Voltage-Gated Ion Channel plates (Thermo Fisher Scientific, Waltham, MA, USA). Three plates were run for each cell line using RNA extracted on three separate days, thus representing three biologic replicates. The Step One Plus Real Time PCR system (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) was used for all quantitative PCR experiments. Box-plots were constructed using GenEx v.6.1 (MultiD Analyses AB, Göteborg, Sweden). Raw threshold cycle (Ct) values were loaded into GenEx v.6.1 (MultiD Analyses AB, Göteborg, Sweden) and normalized to expression of the reference genes GAPDH, HPRT1, and GUSB. Relative fold changes were calculated using the $2^{-\Delta\Delta \text{Ct}}$ method with fibroblast cell lines as the referent and transformed to a log$_2$ scale. Raw Ct data, as well as normalized data for sodium channel expression, are provided in Supplemental Datasets S3 and Supplemental Dataset S4, respectively.

2.4. Kaplan–Meier Analysis

Kaplan–Meier curves based on tumor VGSC expression were generated for overall survival (OS) using KMplot software, from a database of public microarray datasets derived from tumors of ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (http://kmplot.com/analysis) (accessed on 26 February 2018) [40]. Results were analyzed from 699 ovarian cancer patients (539 confirmed serous, 19 confirmed endometrioid, 141 unknown histology) known to have undergone optimal surgical cytoreduction (<1 cm residual disease) and received platinum-based chemotherapy. Data from outlier microarrays (as defined by the KMplot software) were excluded. The actual number of patients for analysis of each gene varied by the presence of the mRNA probes on the included microarrays. For each gene, the optimal microarray probe was selected according to the Jetset method described by Li, et al. [41]. Samples were split into high and low expression groups using a published method for determining the best performing threshold as a cutoff and compared using a log-rank test [42].

2.5. Cell Lines and Culture Conditions

The human high-grade serous ovarian cancer cell lines KURAMOCHI, OVCAR3, OVCAR5, JHOS4, and OVSAHO were a gift from Dr. Dipanjan Chowdhury (Dana-Farber Cancer Institute, Boston, MA, USA) and have been previously characterized [43,44]. Human fibroblast cell lines BJ and WI 38, human breast cancer cell line T47D, and human choriocarcinoma cell lines JEG3 and JAR were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA).

OVCAR3, OVCAR5, and T47D cells were routinely cultured with RPMI 1640 medium (ATCC) supplemented with 1% penicillin-streptomycin (ATCC) and 10% or, for OVCAR3, 20%, fetal bovine serum (FBS) (ATCC). The OVCAR3 and T47D culture medium additionally contained 0.01 units/mL and 0.02 units/mL insulin, respectively. KURAMOCHI and OVSAHO were cultured with DMEM/F12 (ATCC) supplemented with 1% penicillin-streptomycin (ATCC) and 10% FBS (ATCC). JEG3, JAR, WI 38, and BJ were grown in Eagle’s Minimal Essential Medium (EMEM; ATCC) supplemented with 10% FBS plus 1% penicillin-streptomycin. Cells were grown in 10 cm diameter tissue culture dishes (BD Biosciences, San Jose, CA, USA) and were maintained in a humidified 5% CO$_2$ atmosphere at 37 °C. Cells were plated for assays from culture plates in log growth phase, at approximately 70–90% confluence. All cells were tested negative for mycoplasma via a PCR assay (Charles River Laboratories, Wilmington, MA, USA). Cell line identities were
verified by short tandem repeat (STR) testing using the commercially available PowerPlex®
18D Kit (Promega, Madison, WI, USA).

2.6. Drugs

The local anesthetic agents lidocaine, bupivacaine, benzocaine, and procaine and the
chemotherapeutic agents carboplatin and paclitaxel were purchased as salts from Sigma-
Aldrich (St. Louis, MO, USA). The sodium channel inhibitors zonisamide and rufinamide
were purchased as salts from Selleck Chemicals (Houston, TX, USA).

Stock solutions of all drugs were prepared by dissolving the drugs in sterile water,
extcept for the stock solutions of benzocaine and paclitaxel, which were prepared by
dissolving the drugs in ethanol. The stock solutions were aliquoted and stored at −20 °C.
The stock solution concentrations were based on the manufacturer stated limits of solubility
of the compounds. Immediately prior to use, final test concentrations were achieved by
making a serial dilution of stock solutions with standard growth medium.

2.7. Cell Proliferation Assays

All cells were plated in triplicate in 96-well tissue culture plates (BD Biosciences) at a
density of 2000 cells per well and allowed to attach overnight.

For construction of IC\textsubscript{50} curves, cells were then incubated with a serial dilution range
of bupivacaine (6 uM to 3.75 mM), lidocaine (0.2 to 125 mM), benzocaine (8 uM to 5 mM) or
procaine (0.02 to 12.5 mM). An equivalent volume percent of ethanol was used as a control
for possible changes to serum concentration within the wells. In all assays, standard growth
medium alone was used as a negative control. Initially, cell proliferation was assessed at
both 48-h and 96-h time points; however, it soon became clear that 48 h was sufficient to
see drug effects, thus this time point was used for subsequent studies.

For studying the effect of local anesthetics combined with chemotherapy, cell lines
were allowed to attach overnight, then first incubated in standard growth medium in the
presence or absence of 10 mM lidocaine or 1 mM bupivacaine (these concentrations being
near the half-maximal inhibitory concentration [IC\textsubscript{50}] for most of the cell lines) for 24 h.
Then the medium was removed, and a logarithmic concentration range of chemotherapy
was added. Cells were incubated with chemotherpay for 72 h.

To study the effect of AEDs, cells were treated with 50 uM or 500 uM rufinamide and
zonisamide for 4 h. Standard growth medium was used as a negative control. Cells were
incubated for 72 h prior to the MTT assay.

Cell proliferation was measured using a thiazolyl blue tetrazolium bromide assay
(MTT; Sigma-Aldrich). After treatment, the medium was removed, and the cells were
incubated with 20 uL MTT reagent (5 mg/mL; Sigma-Aldrich) in the dark for four hours.
MTT is a yellow soluble salt that is converted to dark blue, insoluble formazan by mito-
chondrial oxidoreductases of viable cells. The formazan crystals were solubilized with
acidified isopropanol (Thermo Fisher Scientific, Waltham, MA, USA) and quantified by
absorbance spectrophotometry at a wavelength of 570 nm using a plate reader (Biotek,
Winooski, VT, USA). The absorbance of the control group without treatment was defined
as 100%, and the absorbance of the other groups was calculated relative to the control.

2.8. Statistical Analysis

All experiments were repeated at least three times. IC\textsubscript{50} values were constructed using
four-parameter nonlinear regression. If the predicted IC\textsubscript{50} value was beyond the range
of concentrations tested experimentally, then the IC\textsubscript{50} was considered not reached. The
area under the curve (AUC) was calculated using the trapezoid rule as a pharmacokinetic
cumulative measurement of drug effect [45]. A lower IC\textsubscript{50} or AUC indicates greater drug
potency or cell line sensitivity, respectively. For statistical comparisons of IC\textsubscript{50} values
or AUC, Student’s t-test was used. For comparisons of groups, one-way ANOVA and
two-way ANOVA tests were used where appropriate. An alpha value <0.05 was considered
statistically significant. Analyses were performed using GraphPad Prism v.6 (San Diego,
CA, USA). For qRT-PCR analysis, relative quantities of sodium channel expression between ovarian cancer lines and fibroblast cell lines were compared in GenEx v.6.1 (MultiD Analyses AB, Göteborg, Sweden) using a \( t \)-test with Dunn–Bonferroni correction for multiple testing.

3. Results

3.1. VGSC Expression in Ovarian Cancer Cell Lines

The Cancer Cell Line Encyclopedia contained VGSC RNAseq data on 48 ovarian cancer cell lines (Supplemental Dataset 1). Across histologic subtypes of ovarian cancer, most VGSC were expressed, except SCN10A. The most highly expressed VGSC were SCN1B and SCN8A (Figure 1A). To compare the relative expression of VGSC in EOC cells to normal tissues, we used a previously published RNAseq dataset (Supplemental Dataset 2) from our laboratory comparing EOC cells to benign fallopian tube secretory epithelial cells (FTSEC), believed to be the cells of origin for most EOC (Figure 1B). Interestingly, while confirmed as the two highest expressed VGSC among the EOC cell lines, both SCN1B (−864 fold; \( p < 0.001 \)) and SCN8A (−21 fold; \( p < 0.001 \)) were expressed at markedly lower levels in EOC compared to FTSEC. We considered the possibility that fallopian tube cells might have unusually high expression levels of these VGSC. Therefore, both to validate the RNAseq expression data and to test this hypothesis, we measured relative VGSC expression in the EOC cell lines OVCAR5 and KURAMOCHI compared to the fibroblast cell lines BJ and WI 38 by qRT-PCR (Figure 1C). Once again, compared to the benign cell lines, the EOC cell lines had significantly lower expression of the VGSC SCN8A (−12 fold) and SCN1B (−10 fold), as well as SCN2A (−259 fold) and SCN9A (−3113 fold) (all \( p < 0.001 \)).

Figure 1. (A) Expression of voltage-gated sodium channels by RNAseq among 48 ovarian cancer cell lines in the Cancer Cell Line Encyclopedia. (B) Relative expression of voltage-gated sodium channels by RNAseq in epithelial ovarian cancer cells (EOC) compared to fallopian tube secretory epithelial cells (FTSEC). (C) Box and whisker plots showing relative expression of voltage-gated sodium channels by qRT-PCR in EOC versus fibroblasts. \(* * * p < 0.001\) Adjusted for multiple testing.

3.2. Prognostic Implications for VGSC Expression in Ovarian Cancer

Based on the cell line data, we focused on the relationship between SCN8A and SCN1B tumor expression and overall survival from EOC after optimal cytoreductive surgery followed by platinum-based chemotherapy. Lower expression of SCN8A was
strongly associated with improved OS (median OS 111 months vs. 52 months; HR = 2.04 [1.21–3.44; p = 0.007]), while lower expression of SCN1B was associated with poorer OS (median OS 45 months vs. 56 months; HR = 0.69 [0.54–0.87; p = 0.002]) (Figure 2A,B).

Figure 2. Overall survival after optimal cytoreductive surgery followed by platinum-based chemotherapy stratified by tumor voltage gated sodium channel expression of (A) SCN8A and (B) SCN1B.

3.3. Effects of AEDs on EOC Cells

The contrasting prognostic significance of SCN8A and SCN1B tumor expression raised the possibility that VGSC blockade could be either helpful or harmful EOC. To examine this further, we tested the effects of sodium channel blockade in vitro. We began by testing the effects of VGSC inhibition using AEDs. EOC cell lines were treated at either low (50 µM) or high (500 µM) concentrations using either of two AEDs, zonisamide and rufinamide, known to be semi-selective sodium channel inhibitors (Figure 3). At the higher concentrations, but not the lower concentrations, both drugs moderately inhibited EOC proliferation with an average change across the EOC cell lines of −13% ± 3.8% (p < 0.001) for zonisamide and −21% ± 3.8% (p = 0.005) for rufinamide.

Figure 3. Effect of treatment with anti-epileptic drugs (AEDs) on epithelial ovarian cancer cell proliferation. Two-way ANOVA adjusted for multiple comparisons.
3.4. Effects of Local Anesthetics on Cell Proliferation

As noted above, local anesthetics are another class of VGSC inhibitors and are more likely to be given to EOC patients. Whereas AEDs prolong the inactivation state of VGSC by stabilizing the inactive state and preventing the return of the channels to the active form, local anesthetics stabilize the open state of the sodium channel, thus preventing depolarization. We tested the effects of two amide local anesthetics (lidocaine and bupivacaine) and two ester local anesthetics (benzocaine and procaine) using serial dilution curves. Several non-ovarian cancer cell lines were also included to test for the specificity of any observed effects. An isovolumetric titration curve of ethanol was used as a negative control with no significant toxicity seen (Figure S1).

The local anesthetics caused concentration-dependent decreases in cell proliferation in all the cells lines (Figure 4A–D). On balance, the magnitude of the effects was greater than those seen with the AEDs. IC\textsubscript{50} values were calculated for each local anesthetic, except for benzocaine, where IC\textsubscript{50} values were not reached (Table S1). Across all cell lines, the mean IC\textsubscript{50} value of bupivacaine (1.7 mM) was significantly lower than either lidocaine (6.2 mM; \(p < 0.001\)) or procaine (8.3 mM; \(p = 0.035\)). As bupivacaine and lidocaine are the most clinically relevant compounds for perioperative management, these were then selected for subsequent studies.

![Graphs showing concentration-dependent effects of local anesthetics on cell proliferation in various cell lines for (A) lidocaine, (B) bupivacaine, (C) procaine, and (D) benzocaine.](image)

3.5. Impact of Local Anesthetic Exposure on Subsequent Response to Chemotherapy

We next investigated how modulating VGSC function might impact subsequent chemotherapy response. Ovarian cancer cell lines or fibroblast cell lines (as controls) were treated with a 24-h pulse of 10 mM lidocaine or 1mM bupivacaine (chosen from the IC\textsubscript{50} curves). The media were then removed, and cells were treated with the two most commonly used drugs in ovarian cancer chemotherapy, carboplatin or paclitaxel, for 72 h.

The addition of local anesthetics shifted the cell proliferation curves downward for all the cell lines, resulting in lower AUC for the chemotherapeutic agents (Figure 5A–J; Figure 6A,B). However, while both cell types showed similar reductions in AUC after exposure to lidocaine (Figure 6C), the effect of bupivacaine was cell type-specific, as ovarian cancer cells showed much greater reductions in AUC after exposure to bupivacaine for both carboplatin (−1.02 [−37%] vs. −0.39 [−16%], \(p = 0.003\)) and paclitaxel (−0.82 [−37%] vs. −0.52 [22%], \(p = 0.02\)) compared to fibroblasts (Figure 6D).
Figure 5. Effects of lidocaine and bupivacaine on ovarian cancer cell (KURAMOCHI, OVSAHO, OVCAR5) or fibroblast (BJ, WI38) responses to carboplatin treatment (A–E) or paclitaxel treatment (F–J).

Figure 6. Change in AUC after addition of local anesthetic for (A) carboplatin and (B) paclitaxel by cell line. Comparisons for each cell line are relative to chemotherapy alone. Relative change in AUC between fibroblasts and ovarian cancer cells after addition of local anesthetic for (C) carboplatin and (D) paclitaxel. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns—not significant.

4. Discussion

Aberrant ion channel expression is a hallmark of many different types of human cancers [6,46]. Depending on the cellular context, VGSC have been characterized as both potentiating or suppressing tumor growth [5,47–49]. In this report, we have identified that most VGSC are expressed in ovarian cancer cells, but at lower expression levels than in normal tissues. While individual VGSC can be associated with either improved or poorer
prognoses for EOC patients, on balance it appears that inhibition of VGSC in EOC has a generally inhibitory effect on cell growth. In addition, these data suggest that exposure to local anesthetics may influence the subsequent effectiveness of chemotherapy in EOC and that this may be a cell type and drug-specific effect.

Our results are consistent with prior reports that have suggested that local anesthetics may directly influence cancer cell growth and response to chemotherapy [16–18,50–52]. For example, combined treatment with lidocaine and cisplatin promoted a higher level of breast cancer cell apoptosis than singular lidocaine or cisplatin treatment via demethylation of RARβ2 and RASSF1A [45]. In another study, for mice bearing leukemic cells, intraperitoneal administration of cisplatin combined with procaine on days 1 and 5 produced 33% and 50% cure rates, while the cure rates obtained with cisplatin alone were 17% and 9%, respectively [53]. Furthermore, novel complexes of platinum and lidocaine or platinum and procaine are both more active compounds against cancer cells than platinum alone [54,55]. However, making general conclusions from these studies has been difficult. Most of these studies reviewed one drug only with great variation in dose ranges (often several orders of magnitude) among studies. Additionally, most of these articles studied the effects on only one cell line, and only a few compared tumor cells to non-tumor cells.

Another study on local anesthetics and ovarian cancer, by Xuan, et al., supports our findings [52]. The authors found that clinically relevant concentrations of bupivacaine enhanced sensitivity to paclitaxel chemotherapy. Unfortunately, they described only one ovarian cancer cell line, and the cell line they used, SKOV3, has recently been classified as a poor ovarian cancer model [56]. Here, we have shown that this inhibitory effect of local anesthetics holds true across several ovarian cancer cell lines with higher fidelity to human tumors, and we have also added a prognostic role for VGSC using data from patient specimens [43,44].

While there are possible beneficial effects of combining chemotherapy and local anesthetics, interactions between VGSC and chemotherapy have also been linked to increased toxicities for both platinum and taxane therapies. Oxaliplatin causes apoptosis in neuronal cells by slowing ion currents across VGSC [57,58]. Moreover, genetic polymorphisms in VGSC have been associated with the risk of oxaliplatin-induced chronic peripheral neuropathy [59–61]. Similarly, VGSC are affected by the polymerization of tubulin. Paclitaxel, which enhances tubulin polymerization, impairs both slow and fast inactivation of VGSC [62]. These effects have been connected to the increased incidence of cardiac arrhythmias during taxane therapy [63].

Our study does have some important limitations. The patient data that we used were compiled from microarray gene expression profiles of tumor specimens. These are retrospective data, and we do not have extensive clinical information on these samples to understand whether the patients were exposed to local anesthetics during their therapy. In some studies, use of local anesthetics has been associated with improved EOC survival [28,64]. However, this benefit would presumably only extend to patients with higher VGSC tumor expression, which would be expected to dilute the effect of low VGSC as a positive prognostic marker. We also did not explore protein-level expression of VGSC. A protein biomarker which could be assessed by immunohistochemistry or Western blot would be much more useful for clinical application. Moreover, differences in mRNA may not always translate into protein expression differences. In future studies, we hope to assess the mechanism of VGSC inhibition in ovarian cancer more in-depth and plan to include protein level assessments in these investigations. Another limitation is that we do not know the individual effects of each VGSC. While this could be studied by knocking down specific VGSC in vitro, in practice, the clinical relevance for this would be limited, as drugs do not exist with this level of channel selectivity. However, development of channel-selective agents may be an important area for future research. To this end, it would also be interesting to examine individual cancer cell lines with extremes of response to VGSC inhibition to elucidate more precisely the mechanism underlying these differences. We hope to address this in future studies. In conclusion, expression of VGSC in ovarian
tumors is prognostic of overall survival for EOC after optimal surgery and platinum-based chemotherapy. Targeting VGSC may augment responses to carboplatin and paclitaxel chemotherapy. If so, novel agents could offer a new adjunct to enhance current therapeutic strategies, and ion channels may be interesting prognostic biomarkers to include in clinical studies. These efforts must be undertaken carefully given the potential for VGSC to increase chemotherapy toxicity. Ultimately, understanding the ion channel expression of individual EOCs before cancer treatment may lead to more effective individualized/personalized anti-cancer regimens.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13215437/s1, Figure S1: Isovolumetric ethanol control curve, Table S1: IC$_{50}$ values for local anesthetics by cell line, Dataset S1: Expression of voltage-gated sodium channels by RNAseq from the Cancer Cell Line Encyclopedia, Dataset S2: Relative expression of voltage-gated sodium channels in ovarian cancer cells relative to fallopian tube secretory epithelial cells by RNAseq, Dataset S3: Raw qRT-PCR data for voltage gated channel PCR array, Dataset S4: Normalized relative expression data for voltage gated sodium channels.

Author Contributions: Conceptualization, K.M.E. and G.F.; methodology, I.S.B. and K.M.E.; software, K.M.E.; validation, I.S.B. and K.M.E.; formal analysis, I.S.B., G.F. and K.M.E.; investigation, I.S.B., K.M.E., S.J.F. and K.T.H.; resources, K.M.E. and G.F.; data curation, I.S.B., G.F. and K.M.E.; writing—original draft preparation, I.S.B. and K.M.E.; writing—review and editing, I.S.B., G.F. and K.M.E.; visualization, I.S.B. and K.M.E.; supervision, K.M.E. and G.F.; project administration, K.M.E. and G.F.; funding acquisition, K.M.E. and G.F. All authors have read and agreed to the published version of the manuscript.

Funding: Ruth N. White Research Fellowship in Gynecologic Oncology (S.J.F.), the Saltonstall Research Fund (S.J.F., K.M.E.), the Potter Research Fund (S.J.F., K.M.E.), the Sperling Family Fund Fellowship (S.J.F., K.M.E.), the Bach Underwood Fund (S.J.F., K.M.E.), Robert and Deborah First Family Fund (S.J.F., K.M.E.), NICHD K12HD13015 (K.M.E.), Honorable Tina Brozman Foundation (K.M.E.). The funding sources had no role in the design of this study or the reporting of the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the supplementary data. Additional data are available on request from the corresponding author.

Conflicts of Interest: The authors have no financial conflict to disclose.

References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef]
2. Kurta, M.L.; Edwards, R.P.; Moysich, K.B.; McDonough, K.; Bertolet, M.; Weissfeld, J.L.; Catov, J.M.; Modugno, F.; Bunker, C.H.; Ness, R.B.; et al. Prognosis and Conditional Disease-Free Survival Among Patients with Ovarian Cancer. J. Clin. Oncol. 2014, 32, 4102–4112. [CrossRef] [PubMed]
3. Dao, F.; Schlappe, B.A.; Tseng, J.; Lester, J.; Nick, A.M.; Lutgendorf, S.K.; McMeekin, S.; Coleman, R.L.; Moore, K.N.; Karlan, B.Y.; et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol. Oncol. 2016, 141, 260–263. [CrossRef] [PubMed]
4. Brevet, M.; Ahidouch, A.; Sevestre, H.; Merviel, P.; El Hiani, Y.; Robbe, M.; Ouadid-Ahidouch, H. Expression of K+ channels in normal and cancerous human breast. Histol. Histopathol. 2008, 23, 965–972.
5. Bon, E.; Driffort, V.; Gradek, F.; Martinez-Caceres, C.; Anchelin, M.; Pelegrin, P.; Cayuela, M.-L.; Lambot, S.M.; Oullier, T.; Guibon, R.; et al. SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer. Nat. Commun. 2016, 7, 13648. [CrossRef]
6. Lastraioili, E.; Iorio, J.; Arcangeli, A. Ion channel expression as promising cancer biomarker. Biochim. Biophys. Acta 2015, 1848, 2685–2702. [CrossRef]
7. Fraser, S.P.; Diss, J.K.J.; Chioni, A.-M.; Mycielska, M.E.; Pan, H.; Yamaci, R.F.; Pani, F.; Siwy, Z.; Krasowska, M.; Grzywna, Z.; et al. Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis. Clin. Cancer Res. 2005, 11, 5381–5389. [CrossRef] [PubMed]
8. Laniado, M.E.; Lalani, E.-N.; Fraser, S.P.; Grimes, J.A.; Bhangal, G.; Djamgoz, M.B.; Abel, P.D. Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am. J. Pathol. 1997, 150, 1213–1221. [PubMed]
9. Prevarskaya, N.; Skryma, R.; Bidaux, G.; Flourakis, M.; Shuba, Y. Ion channels in death and differentiation of prostate cancer cells. *Cell Death Differ.* 2007, 14, 1295–1304. [CrossRef] [PubMed]

10. Nelson, M.; Yang, M.; Millican-Slater, R.; Brackenbury, W.J. Nav1.5 regulates breast tumor growth and metastatic dissemination in vivo. *Oncotarget* 2015, 6, 32914–32929. [CrossRef]

11. Nelson, M.; Yang, M.; Dowle, A.A.; Thomas, J.R.; Brackenbury, W.J. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. *Mol. Cancer* 2015, 14, 13–17. [CrossRef] [PubMed]

12. Abdul, M.; Hoosein, N. Voltage-gated sodium ion channels in prostate cancer: Expression and activity. *Anticancer Res.* 2002, 22, 1727–1730.

13. Olsen, C.M.; Meussen-Elholm, E.T.; Røste, L.S.; Taubøll, E. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. *Mol. Cell. Endocrinol.* 2004, 213, 173–179. [CrossRef]

14. Zhang, L.; Wang, G.; Wang, L.; Song, C.; Leng, Y.; Wang, X.; Kang, J. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. *Mol. Cell. Biochem.* 2011, 361, 39–45. [CrossRef]

15. Boselli, E.; Duflo, F.; DeBon, R.; Allaouchiche, B.; Chassard, D.; Thomas, L.; Portoukalian, J. The Induction of Apoptosis by Local Anesthetics: A Comparison between Lidocaine and Ropivacaine. *Anesth. Analg.* 2003, 96, 755–756. [CrossRef] [PubMed]

16. Bundschuerer, A.; Malsy, M.; Gebhardt, K.; Metterlein, T.; Plank, C.; Wiese, C.; Gruber, M.; Graf, B. Effects of ropivacaine, bupivacaine and sufentanil in colon and pancreatic cancer cells in vitro. *Pharmacol. Res.* 2015, 95–96, 126–131. [CrossRef] [PubMed]

17. Chang, Y.-C.; Hsu, Y.-C.; Liu, C.-L.; Huang, S.-Y.; Hu, M.-C.; Cheng, S.-P. Local Anesthetics Induce Apoptosis in Human Thyroid Cancer Cells through the Mitogen-Activated Protein Kinase Pathway. *PloS ONE* 2014, 9, e89563. [CrossRef]

18. Chang, Y.-C.; Liu, C.-L.; Chen, M.-J.; Hsu, Y.-W.; Chen, S.-N.; Lin, C.-H.; Chen, C.-M.; Yang, F.-M.; Hu, M.-C. Local Anesthetics Induce Apoptosis in Human Breast Tumors Cells. *Anesth. Analg.* 2014, 118, 116–124. [CrossRef]

19. Yoon, J.R.; Whipple, R.A.; Balzer, T.; Partanen, K.; Raman, M.A.; Peckham, M.; Martin, S.S. Local anesthetics inhibit kinesin motility and microtubule protrusions in human epithelial and breast tumor cells. *Breast Cancer Res. Treat.* 2011, 129, 691–701. [CrossRef] [PubMed]

20. Beverly, A.; Kaye, A.D.; Ljungqvist, O.; Urman, R.D. Essential Elements of Multimodal Analgesia in Enhanced Recovery After Surgery (ERAS) Guidelines. *Clin. Pain.* 2017, 35, e115–e143. [CrossRef] [PubMed]

21. Gustafsson, U.O.; Oppelstrup, H.; Thorell, A.; Nygren, J.; Ljungqvist, O. Adherence to the ERAS protocol is associated with 5-Year Survival After Colorectal Cancer Surgery: A Retrospective Cohort Study. *World J. Surg.* 2016, 40, 1741–1747. [CrossRef] [PubMed]

22. De Oliveira, G.S.; Fitzgerald, P.; Streicher, L.F.; Marcus, R.J.; McCarthy, R.J. Systemic lidocaine to improve postoperative quality of recovery after ambulatory laparoscopic surgery. *Anesth. Analg.* 2012, 115, 262–267. [CrossRef]

23. Marret, E.; Rolin, M.; Beaussier, M.; Bonnet, F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. *BJS* 2008, 95, 1331–1338. [CrossRef]

24. Scott, D.B.; Jebson, P.J.R.; Braid, D.P.; Ortengren, B.; Frisch, P. Factors affecting plasma levels of lignocaine and prilocaine. *Br. J. Anaesth.* 1972, 44, 1040–1049. [CrossRef] [PubMed]

25. Sharrock, N.E.; Mineo, R.; Stanton, J.; Ennis, W.J., 3rd; Urman, R.D.; Arthur, G.R. Single versus staged epidural injections of 0.75% bupivacaine: Pharmacokinetic and pharmacodynamic effects. *Anesth. Analg.* 1994, 79, 307–312. [CrossRef] [PubMed]

26. Chen, W.-K.; Miao, C.-H. The Effect of Anesthetic Technique on Survival in Human Cancers: A Meta-Analysis of Retrospective and Prospective Studies. *PloS ONE* 2013, 8, e56540. [CrossRef]

27. Cummings, K.C.; Xu, F.; Cummings, L.C.; Cooper, G.S. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: A population-based study. *Anesthesiology* 2012, 116, 797–806. [CrossRef]

28. De Oliveira, G.S.; Ahmad, S.; Schink, J.C.; Singh, D.K.; Fitzgerald, P.C.; McCarthy, R.J. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. *Reg. Anesth. Pain Med.* 2011, 36, 271–277. [CrossRef]

29. Exadaktylos, A.K.; Buggy, D.J.; Moriarty, D.C.; Mascha, E.; Sessler, D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? *Anesthesiology* 2006, 105, 660–664. [CrossRef] [PubMed]

30. Forget, P.; Tombal, B.; Scholtes, J.-L.; Nzimbalaza, J.; Meulders, C.; Legrand, C.; Van Cangh, P.; Cosyns, J.-P.; De Kock, M. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? *Eur. J. Anaesthesiol.* 2011, 28, 830–835. [CrossRef] [PubMed]

31. Lacassie, H.J.; Cartagena, J.; Brañes, J.; Assel, M.; Echevarría, G.C. The Relationship between Neuraxial Anesthesia and Advanced Ovarian Cancer-Related Outcomes in the Chilean Population. *Anesth. Analg.* 2013, 117, 653–660. [CrossRef] [PubMed]

32. Merquiol, F.; Montelimal, A.S.; Nourissat, A.; Molliex, S.; Zufferey, P.J. Cervical epidural anesthesia is associated with increased cancer-free survival in laryngeal and hypopharyngeal cancer surgery: A retrospective propensity-matched analysis. *Reg. Anesth. Pain Med.* 2013, 38, 398–402. [CrossRef] [PubMed]

33. Ross, M.; Schiffmann, J.; Tennesstedt, P.; Kessler, T.; Blanc, I.; Goetz, A.; Scholmm, T.; Graeven, M.; Reuter, D. Oncological long-term outcome of 4772 patients with prostate cancer undergoing radical prostatectomy: Does the anaesthetic technique matter? *Eur. J. Surg. Oncol.* 2014, 40, 1686–1692. [CrossRef]

34. Sun, Y.; Li, T.; Gan, T.J. The Effects of Perioperative Regional Anesthesia and Analgesia on Cancer Recurrence and Survival After Oncology Surgery: A Systematic Review and Meta-Analysis. *Reg. Anesth. Pain Med.* 2015, 40, 589–598. [CrossRef]
35. Wuethrich, P.Y.; Hsu Schmitz, S.F.; Kessler, T.M.; Thalmann, G.N.; Studer, U.E.; Stuebe, F.; Burkhard, F.C. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: A retrospective study. *Anesthesiology* 2010, 113, 570–576. [CrossRef]

36. Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. *Nature* 2015, 528, 84–87. [CrossRef]

37. Barretina, J.; Caponigro, G.; Stranks, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehár, J.; Kryukov, G.V.; Sonkin, D.; et al. The Cancer Cell Line Encyclopedia provides predictive modelling of anticancer drug sensitivity. *Nature* 2012, 483, 603–607. [CrossRef]

38. Elias, K.M.; Emori, M.M.; Westerling, T.; Long, H.; Budina-Kolomets, A.; Li, F.; Macduffie, E.; Davis, M.; Holman, A.; Lawney, B.; et al. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. *JCI Insight* 2016, 1. [CrossRef] [PubMed]

39. Trapnell, C.; Roberts, A.; Goff, L.; Pertea, G.; Kim, D.; Kelley, D.R.; Pimentel, H.; Salzberg, S.L.; Rinn, J.L.; Pachter, L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat. Protoc.* 2012, 7, 562–578. [CrossRef] [PubMed]

40. Gyorffy, B.; Lançzy, A.; Eklund, A.C.; Denkert, C.; Budczies, J.; Li, Q.; Szallasi, Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res. Treat.* 2009, 123, 725–731. [CrossRef]

41. Li, Q.; Birkbak, N.J.; Gyorffy, B.; Szallasi, Z.; Eklund, A.C. Jetset: Selecting the optimal microarray probe set to represent a gene. *BMC Bioinform.* 2011, 12, 474. [CrossRef] [PubMed]

42. Mihály, Z.; Kormos, M.; Lançzy, A.; Dank, M.; Budczies, J.; Szász, A.M.; Gyorffy, B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. *Breast Cancer Res. Treat.* 2013, 140, 219–232. [CrossRef] [PubMed]

43. Domcke, S.; Sinha, R.; Levine, D.A.; Sander, C.; Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. *Nat. Commun.* 2013, 4, 2126. [CrossRef] [PubMed]

44. Elias, K.M.; Emori, M.M.; Papp, E.; MacDuffie, E.; Konecny, G.E.; Velculescu, V.E.; Drapkin, R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. *Gynecol. Oncol.* 2015, 139, 97–103. [CrossRef]

45. Jang, I.S.; Neto, E.C.; Guinney, J.; Friend, S.H.; Margolin, A.A. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. *Biocomputing 2013*, 2014, 63–74. [CrossRef]

46. Biasiotta, A.; D’Arcangelo, D.; Passarelli, F.; Nicodemi, E.M.; Facchiano, A. Ion channels expression and function are strongly modified in solid tumors and vascular malformations. *J. Transl. Med.* 2016, 14, 285. [CrossRef]

47. Hernandez-Plata, E.; Ortiz, C.S.; Marquina-Castillo, B.; Medina-Martínez, I.; Alfaro, A.; Berumen, J.; Rivera, M.; Gomora, J.C. Overexpression of NaV1.6 channels is associated with the invasion capacity of human cervical cancer. *Int. J. Cancer* 2011, 130, 2013–2023. [CrossRef] [PubMed]

48. Besson, P.; Driffort, V.; Bon, Éméline; Gradek, F.; Chevalier, S.; Roger, S. How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? *Biochim. Biophys. Acta* 2015, 1848, 2493–2501. [CrossRef] [PubMed]

49. Qian, Y.; Wong, C.C.; Xu, J.; Chen, H.; Zhang, Y.; Kang, W.; Wang, H.; Zhang, L.; Li, W.; Chu, E.S.; et al. Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation. *Cancer Res.* 2017, 77, 1968–1982. [CrossRef]

50. Kobayashi, K.; Ohno, S.; Uchida, S.; Amano, O.; Sakagami, H.; Nagasaka, H. Cytotoxicity and type of cell death induced by local anesthetics in human oral normal and tumor cells. *Anesthesiology* 2012, 116, 3292–3293. [PubMed]

51. Werdehausen, R.; Fazieli, S.; Braun, S.; Herrmanns, H.; Essmann, F.; Hollmann, M.W.; Bauer, I.; Stevens, M.F. Apoptosis induction by different local anesthetics in a neuroblastoma cell line. *Br. J. Anaesth.* 2009, 103, 711–718. [CrossRef]

52. Xuan, W.; Zhao, H.; Hankin, J.; Chen, L.; Yao, S.; Ma, D. Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro. *Sci. Rep.* 2016, 6, 26277. [CrossRef] [PubMed]

53. Esposito, M.; Fulco, R.A.; Collecchi, P.; Zicca, A.; Cadoni, A.; Merlo, F.; Rosso, R.; Sobrero, A. Improved Therapeutic Index of Cisplatin by Procaine Hydrochloride. *J. Natl. Cancer Inst.* 1990, 82, 677–684. [CrossRef]

54. Tabrizi, L.; Chiniforoshan, H. Cytotoxicity and cellular response mechanisms of water-soluble platinum(II) complexes of lodicaine and phenylcyanamide derivatives. *BioMetals* 2016, 30, 59–70. [CrossRef]

55. Viale, M.; Pastrone, M.; Pellecchia, C.; Vannozzi, M.O.; Cafaggi, S.; Esposito, M. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. *Anti-Cancer Drugs* 1998, 9, 457–463. [CrossRef]

56. Beaufort, C.M.; Helmijr, J.C.A.; Piskorz, A.M.; Hoogstraat, M.; Ruigrok-Ristier, K.; Besselink, N.; Murtaza, M.; van Ijcken, W.; Heine, A.; Smid, M.; et al. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. *PLoS ONE* 2014, 9, e103988. [CrossRef] [PubMed]

57. Wu, S.-N.; Chen, B.-S.; Wu, Y.-H.; Peng, H.; Chen, L.-T. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. *NeuroToxicology* 2009, 30, 677–685. [CrossRef]

58. Grolleau, F.; Gamelin, L.; Boisdron-Celle, M.; Laped, B.; Pelhate, M.; Gamelin, E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. *J. Neurophysiol.* 2001, 85, 2293–2297. [CrossRef] [PubMed]
59. Argyriou, A.A.; Cavaletti, G.; Antonacopoulou, A.; Genazzani, A.A.; Briani, C.; Bruna, J.; Terrazzino, S.; Velasco, R.; Alberti, P.; Campagnolo, M.; et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. *Cancer* 2013, 119, 3570–3577. [CrossRef] [PubMed]

60. Palugulla, S.; Thakkar, D.N.; Kayal, S.; Narayan, S.; Dkhar, S. Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients. *Asian Pac. J. Cancer Prev.* 2017, 18, 3157–3165. [CrossRef] [PubMed]

61. Sereno, M.; Gutiérrez-Gutiérrez, G.; Rubio, J.M.; Apellániz-Ruiz, M.; Sánchez-Barroso, L.; Casado, E.; Falagan, S.; López-Gómez, M.; Merino, M.; Gómez-Raposo, C.; et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. *BMC Cancer* 2017, 17, 63. [CrossRef] [PubMed]

62. Casini, S.; Tan, H.L.; Demirayak, I.; Remme, C.A.; Amin, A.S.; Scicluna, B.P.; Chatyan, H.; Ruijter, J.M.; Bezzina, C.R.; van Ginneken, A.C.; et al. Tubulin polymerization modifies cardiac sodium channel expression and gating. *Cardiovasc. Res.* 2010, 85, 691–700. [CrossRef] [PubMed]

63. Dybkova, N.; Wagner, S.; Backs, J.; Hund, T.J.; Mohler, P.J.; Sowa, T.; Nikolaev, V.O.; Maier, L.S. Tubulin polymerization disrupts cardiac beta-adrenergic regulation of late INa. *Cardiovasc. Res.* 2014, 103, 168–177. [CrossRef] [PubMed]

64. Elias, K.M.; Kang, S.; Liu, X.; Horowitz, N.S.; Berkowitz, R.S.; Freund, G. Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. *Ann. Surg. Oncol.* 2014, 22, 1341–1348. [CrossRef] [PubMed]